ENDOCYTE
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate recept... or positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.
ENDOCYTE
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
1996-01-01
Address:
West Lafayette, Indiana, United States
Country:
United States
Website Url:
http://www.endocyte.com
Total Employee:
51+
Status:
Active
Contact:
(765) 463-7175
Email Addresses:
[email protected]
Total Funding:
114.35 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Amazon Office 365 Mail DMARC Vimeo AWS Global Accelerator Barracuda Networks Akamai DNS
Similar Organizations
Apogenix
Apogenix is a biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases.
Oncotelic Therapeutics
Oncotelic is a biopharmaceutical company, develops anti-vascular therapeutics for patients with cancer and sight-threatening eye diseases.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
MidCap Financial
MidCap Financial investment in Venture Round - Endocyte
Silicon Valley Bank
Silicon Valley Bank investment in Venture Round - Endocyte
Burrill & Company
Burrill & Company investment in Series C - Endocyte
Sanderling Ventures
Sanderling Ventures investment in Series C - Endocyte
Triathlon Medical Venture Partners
Triathlon Medical Venture Partners investment in Series C - Endocyte
Blue Chip Venture Company
Blue Chip Venture Company investment in Series C - Endocyte
Indiana University Health
Indiana University Health investment in Series C - Endocyte
American Bailey Ventures
American Bailey Ventures investment in Series C - Endocyte
American Bailey Ventures
American Bailey Ventures investment in Series C - Endocyte
CID Capital
CID Capital investment in Series C - Endocyte
Official Site Inspections
http://www.endocyte.com
- Host name: 104.18.4.189
- IP address: 104.18.4.189
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Endocyte" on Search Engine
Novartis announces planned acquisition of Endocyte to expand …
Basel, October 18, 2018 - Novartis today announced that it has entered into an agreement and plan of merger with Endocyte, a US-based biopharmaceutical company focused on developing targeted therapeutics for cancer treatment.See details»
Why We Did What We Did: PSMA PET/CT Selection …
Endocyte was founded in 1996 to develop small-molecule drug conjugates and imaging agents targeting the folate receptor . In 2012, Endocyte entered into a license agreement with Merck & Co. for …See details»
Drugmakers go nuclear, continuing push into …
Jun 10, 2021 Endocyte agreed. And everyone ultimately won out from the arrangement. As reported at the American Society of Clinical Oncology (ASCO) annual meeting last …See details»
Why We Did What We Did: PSMA-PET/CT Selection Criteria for …
Jan 27, 2022 While analyzing the failure of the folate-targeted theragnostic trial 3, Endocyte restructured the organization and explored in-licensing opportunities. …See details»
Merck and Endocyte Enter Exclusive Worldwide Agreement to …
Apr 16, 2012 Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary …See details»
Endocyte - Crunchbase Company Profile & Funding
Endocyte is a biopharmaceutical company that develops receptor-targeted therapeutics to treat cancer and inflammatory diseases. Acquired by. Novartis. West Lafayette, Indiana, …See details»
Novartis inks $2.1B Endocyte buyout, furthering radiotherapy push
By Nick Paul Taylor Oct 18, 2018 6:03am. mergers and acquisitions prostate cancer Endocyte EuroBiotech Report. Novartis has struck a $2.1 billion (€1.8 billion) deal to …See details»
Novartis to Buy Biopharmaceutical Company Endocyte for $2.1 …
Oct 18, 2018 Expanding further into the increasingly competitive field of oncology, Swiss drugmaker Novartis AG (NVS) announced on Thursday morning it is buying …See details»
Novartis to acquire US cancer drug developer Endocyte for $2.1bn
Swiss pharmaceutical firm Novartis has signed a $2.1bn deal to purchase all outstanding shares of US-based biopharmaceutical company Endocyte in order to bolster its …See details»
Endocytosis in the context-dependent regulation of individual and ...
Jun 1, 2021 Endocytosis allows cells to transport particles and molecules across the plasma membrane. In addition, it is involved in the termination of signalling through …See details»
ASCO: Novartis backs up $2.1B Endocyte buyout with prostate …
Jun 3, 2021 | Two years after splashing out $2.1 billion on Endocyte, Novartis is unveiling full phase 3 data for the radiopharmaceutical it picked up in that deal.See details»
Endocyte becomes first Purdue startup to reach $1.5B in value
October 3, 2018. Endocyte becomes first Purdue startup to reach $1.5B in value. Endocyte’s primary cancer drug platforms include “two of the most exciting platforms in …See details»
Novartis to acquire Endocyte in $2.1bn deal - Financial Times
Oct 18, 2018 The acquisition of Endocyte, a company specialising in prostate cancer therapies, came as Novartis announced a 6 per cent rise to $12.8bn in net sales in the …See details»
The endocytic pathway: a mosaic of domains - Nature
Oct 1, 2001 Early endosomes exhibit a highly pleiomorphic organization, and transport intermediates formed on early endosomal membranes — along recycling and …See details»
Endocyte: Elucidating The Investment Thesis Of A Stellar Cancer ...
Jun 15, 2018 Endocyte (NASDAQ: ECYT) is a highly interesting company brought to our attention by a subscriber of Integrated BioSci Investing. As an innovator to service the …See details»
Endocyte: Small Company, Small Valuation, Full Pipeline
Jan 30, 2015 Endocyte, Inc. (ECYT) is a biopharmaceutical company based out of West Lafayette, IN. The company is currently developing therapies that target both cancers …See details»
Endocyte - Contacts, Employees, Board Members, Advisors
Endocyte is a biopharmaceutical company that develops receptor-targeted therapeutics to treat cancer and inflammatory diseases.See details»
Endocytosis - Wikipedia
Endocytosis is a cellular process in which substances are brought into the cell. The material to be internalized is surrounded by an area of cell membrane, which then buds off inside …See details»
Organization | Endocyte - CDEK
Organization Overview. First Clinical Trial. 1999 NCT00003763. First Marketed Drug. None First NDA Approval. None Last Known Activity ... Endocyte Active Ingredients. Drugs in …See details»
Endocytic recycling | Nature Reviews Molecular Cell Biology
Feb 1, 2004 Endocytosis in the context-dependent regulation of individual and collective cell properties. Article 01 June 2021. Main. Endocytic membrane traffic in mammalian …See details»